AbbVie (ABBV) Long-Term Debt Repayments (2015 - 2026)

AbbVie (ABBV) has reported Long-Term Debt Repayments for 12 consecutive years, with $2.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Long-Term Debt Repayments fell 46.72% year-over-year to $2.0 billion in Q2 2026; TTM through Jun 2026 was $2.0 billion, a 84.42% decrease from a year earlier, with the FY2025 full-year figure at $6.8 billion, down 29.29% from the prior year.
• Long-Term Debt Repayments was $2.0 billion for Q2 2026 at AbbVie, up from $8.0 million in the prior quarter.
• Over five years, Long-Term Debt Repayments peaked at $6.9 billion in Q4 2022 and troughed at $2.0 million in Q2 2022.
• A 5-year average of $2.2 billion and a median of $1.8 billion in 2023 frame the typical range for Long-Term Debt Repayments.
• Across the five-year window, Long-Term Debt Repayments slumped 99.94% in 2022 and surged 50000.0% in 2023, its largest moves.
• Over 5 years, Long-Term Debt Repayments stood at $6.9 billion in 2022, then sank by 73.81% to $1.8 billion in 2023, then soared by 221.18% to $5.8 billion in 2024, then plunged by 99.86% to $8.0 million in 2025, then jumped by 24900.0% to $2.0 billion in 2026.
• The last three Long-Term Debt Repayments figures came in at $2.0 billion (Q2 2026), $8.0 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.